A drug by AstraZeneca and Amgen designed to treat asthma has been granted a speedy review by the Food and Drug Administration (FDA). The experimental drug tezepelumab aims to reduce asthma attacks for patients with severe and uncontrolled forms of asthma. Both companies expect a decision within the first quarter of 2022 following the application to the FDA. Commenting on the the respiratory condition, Amgen senior executive David Reese states that asthma is a, ‘challenging, complex disease for physicians’ and that there is a ‘high unmet medical need’ to help treat patients with asthma. There are approximately 339 million people around the world that live with asthma, and 10% of those suffer from a more severe form of the condition.

Read more here.

More on: